Primary bile acid malabsorption, a gut defect in the reabsorption of bile acids in the small intestine which results in increased levels of bile acids in the colon leading to watery diarrhea and bloating. Chronic infection of C. difficile, G. lamblia
C. difficile - bacteria that can be the source of diarrhea. G. lamblia - a parasite that can be the source diarrhea.From 1–12 months, typical causes of chronic diarrhea are the following:

Acrodermatitis enteropathica, a condition in which the intestine cannot absorb zinc. Cystic fibrosis, a condition caused by a genetic mutation that can lead to injury to the bodys organs including the lungs and those in the digestive system. Apple juice and pear nectar, the digestive tract of children have difficulty absorbing significant quantities of sugars and carbohydrates which certain fruit juices can have. Celiac Disease, a disorder in which there is an immune response to eating gluten which can eventually cause damage to the small intestine over time and impedes absorption. Food allergy.Most instances of chronic diarrhea in infancy are caused by infectious and post infectious disease of the intestine as well as food sensitivities or allergies. Diagnosis
Diagnosis of toddlers diarrhea involves the evaluation of history of present illness, any relevant past medical history, and physical examination to determine any causative factors to inform treatment regimens and further recommendations.Evaluation of history of present illness includes:
Stool characterization (i.e. appearance, consistency, frequency, etc.) Time frame and duration (important for differentiation between acute and chronic diarrhea)
Food/drink allergies or restrictions (e.g. lactose intolerance)
Medications, especially antibiotics
Infection exposure (e.g.
The FDA granted the approval of Enspryng to Genentech Inc. Satralizumab is the third approved treatment for NMOSD in the United States. Names
Satralizumab is the international nonproprietary name (INN) and the United States Adopted Name (USAN). References
External links
"Satralizumab". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT02028884 for "Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)" at ClinicalTrials.gov</ref>
Clinical trial number NCT02073279 for "Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)" at ClinicalTrials.gov